1-3 of 3
Bernhard Stockmeyer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Humanized HLA-DR Antibody (HU1D10, Apolizumab) in Combination with G-CSF (Filgrastim) for the Treatment of Non-Hodgkin’s Lymphoma: A Pilot Study.

Juergen Rech, MD, Roland Repp, MD, Dorit Rech, MD, Bernhard Stockmeyer, MD, Michael Dechant, MD, Gerald Niedobitek, MD, Tilman Pearce, MD, Georg Weiner, MD, Martin Gramatzki, MD, Thomas Valerius, MD.
Journal: Blood
Blood (2005) 106 (11): 4775.
https://doi.org/10.1182/blood.V106.11.4775.4775
Published: 2005
Journal Articles

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing

Michael Dechant, Gestur Vidarsson, Bernhard Stockmeyer, Roland Repp, Martin J. Glennie, Martin Gramatzki, Jan G. J. van de Winkel, Thomas Valerius
Journal: Blood
Blood (2002) 100 (13): 4574–4580.
https://doi.org/10.1182/blood-2002-03-0687
Published: 2002
Journal Articles

FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy

Thomas Valerius, Bernhard Stockmeyer, Annemiek B. van Spriel, Robert F. Graziano, Ingrid E. van den Herik-Oudijk, Roland Repp, Yashwant M. Deo, John Lund, Joachim R. Kalden, Martin Gramatzki, Jan G.J. van de Winkel
Journal: Blood
Blood (1997) 90 (11): 4485–4492.
https://doi.org/10.1182/blood.V90.11.4485
Published: 1997